Business Context and Reporting Period
This Form 8-K Current Report was filed by Merit Medical Systems, Inc. (MMSI) on January 8, 2026, covering events occurring on January 4, 2026. The filing addresses the departure of the former CEO and Chair, the appointment of new leadership, and the announcement of preliminary unaudited revenue results for the quarter ended December 31, 2025.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing preliminary unaudited revenue for the fourth quarter of 2025. However, the specific revenue figure, profit, cash flow, margins, debt, or liquidity metrics are not explicitly stated within the text of this 8-K document. The filing notes that these preliminary figures are subject to adjustment following customary financial review and audit procedures.
Material Changes and Corporate Governance
- Executive Departure: Fred P. Lampropoulos resigned as President, CEO, and Chair of the Board effective January 4, 2026, citing personal reasons. The resignation is not related to any dispute regarding financial reporting or operations.
- Leadership Transition: F. Ann Millner, Ed.D., formerly the Lead Independent Director, was appointed Chair of the Board effective January 5, 2026.
- Board Composition: The Board size was reduced from eleven to ten members effective January 5, 2026.
- Compensation Arrangement: A consulting agreement was entered into with Mr. Lampropoulos on January 7, 2026, for a three-month period at a rate of $250,000 per month.
Guidance, Outlook, and Risks
Merit Medical Systems plans to report its full fourth quarter and fiscal year 2025 financial results and issue fiscal year 2026 guidance in a future release. The filing includes a Regulation FD disclosure regarding non-GAAP financial measures referenced in the attached press release, with reconciliations to GAAP measures provided in that exhibit. No specific risks or contingencies were detailed in the body of this 8-K beyond standard disclosures regarding the preliminary nature of the revenue data.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific preliminary revenue number for Q4 2025.
- Verify the full fiscal year 2025 financial results and fiscal year 2026 guidance when officially released.
- Confirm the details of the non-GAAP measure reconciliation included in the press release.
- Monitor for the appointment of a new CEO, as the filing only addresses the Board Chair appointment.